Welcome to our dedicated page for Astrotech news (Ticker: ASTC), a resource for investors and traders seeking the latest updates and insights on Astrotech stock.
Astrotech Corporation (Nasdaq: ASTC) is a mass spectrometry company headquartered in Austin, Texas that develops and commercializes technology-driven businesses through its wholly owned subsidiaries. The Astrotech news stream highlights how its core mass spectrometry and gas chromatography technology is being applied in explosives and narcotics trace detection, aviation and cargo security screening, environmental testing, industrial controls, agriculture process analysis, and breath-based VOC analysis related to infections and critical health conditions.
Visitors to this page can review company press releases and other coverage related to Astrotech’s operating milestones. Recent news has described deployments of 1st Detect’s TRACER 1000 explosive and narcotics trace detection systems at airports and cargo facilities, approvals from security authorities for aviation and air cargo screening, and expansion of 1st Detect’s footprint into new regions such as Southeast Asia. Other updates cover the launch and deployment of EN-SCAN environmental testing instruments that integrate gas chromatography and mass spectrometry for real-time air, water, and soil analysis in the field.
Astrotech’s news also addresses corporate and strategic developments, including financial results, participation in investor conferences, executive appointments, and the Board of Directors’ review of strategic alternatives intended to explore options such as equity capital raises, reverse mergers, combination transactions, or potential sales of parts of the business. Investors and analysts following ASTC can use this page to track how the company’s subsidiaries are progressing in markets like security screening, environmental monitoring, industrial manufacturing, and agriculture, as well as to monitor announcements tied to its strategic review and governance activities.
For anyone researching ASTC stock, this news feed offers a centralized view of Astrotech’s operational updates, technology deployments, and capital markets communications over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Astrotech Corporation (Nasdaq: ASTC) announced its Q2 fiscal 2023 results, ending December 31, 2022, reporting a total revenue of $301,000, primarily from its TRACER 1000™ explosive trace detector and related services. The company’s gross margin improved to 38%, up from 18% in the previous year, attributed to higher-margin services. Key developments include the launch of the AgLAB 1000-D2™ for the cannabis industry, which could boost revenues by 45%, and the BreathTest-1000™, which can differentiate between infected and healthy breath samples. Astrotech’s cash and liquid investments stand at $46.8 million, and it successfully regained Nasdaq listing compliance.
Astrotech Corporation (Nasdaq: ASTC) has appointed Thomas B. Pickens III as Chief Technology Officer, complementing his role as CEO. This dual role highlights Pickens' expertise in advancing the company’s proprietary Astrotech Mass Spectrometer Technology (AMS Technology). Since 2017, he has played a crucial role in developing products such as the BreathTest-1000 for COVID-19 detection. Additionally, he is leading initiatives in essential oils distillation using AMS Technology. The company anticipates that this leadership change will enhance commercial value, although it faces uncertainties regarding FDA approvals for its products.
Astrotech Corporation (Nasdaq: ASTC) announced an expansion of its Board of Directors from four to five members, appointing Bob McFarland as a new director. McFarland brings extensive executive management experience, particularly in information technology, having served at the Department of Veterans Affairs as Chief Information Officer. His experience includes significant roles at Dell, where he managed government relations. The Board welcomes McFarland's expertise, particularly as Astrotech develops its mass-spectrometry technologies, including the BreathTest-1000, and navigates FDA approval processes.
FAQ
What is the current stock price of Astrotech (ASTC)?
What is the market cap of Astrotech (ASTC)?
